Recombinant human nerve growth factor injection approved for clinical trial
- Categories:Corporate news
- Author:
- Origin:
- Time of issue:2018-11-28 19:15
- Views:
Recombinant human nerve growth factor injection approved for clinical trial
(Summary description)
On November 28, 2018, the class 1 new biological drug "recombinant human nerve growth factor injection" developed by our company obtained the clinical trial approval document issued by the State Drug Administration.
- Categories:Corporate news
- Author:
- Origin:
- Time of issue:2018-11-28 19:15
- Views:
On November 28, 2018, the class 1 new biological drug "recombinant human nerve growth factor injection" developed by our company obtained the clinical trial approval document issued by the State Drug Administration.
Quick navigation
Home 丨 About us 丨 R & D platform 丨 Product 丨 Contact us
Contact us
Address: Building 7, Kangyuan medical science and Technology Park, 578 longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province
Postal Code: 211100
Contact information: 025-58310595 (switchboard)
Fax: 025-58310595-108
Scan
Copyright © 2021 Jiangsu Zhongxin Pharmaceutical Co., Ltd 苏ICP备11074983号-1 Powered by：www.300.cn
